Personal information

Activities

Collapse all

Works (12)

Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2024-05-14 | Journal article
DOI: 10.1016/j.ejso.2024.108382
PMID: 38763112
Contributors: Czarnecka AM; Ostaszewski K; Błoński P; Szumera-Ciećkiewicz A; Kozak K; Placzke J; Borkowska A; Terlecka A; Rogala P; Świtaj T et al.
Source: Self-asserted source
Krzysztof Ostaszewski

Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma

Biomedicines
2024-03 | Journal article | Author
DOI: 10.3390/biomedicines12030669
Contributors: Piotr Jan Błoński; Anna Czarnecka; Krzysztof Ostaszewski; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Source: check_circle
Multidisciplinary Digital Publishing Institute

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.

Melanoma research
2023-04-03 | Journal article
DOI: 10.1097/cmr.0000000000000885
PMID: 37015054
Contributors: Cybulska-Stopa B; Piejko K; Ostaszewski K; Dziura R; Galus Ł; Ziółkowska B; Kempa-Kamińska N; Marcin Ziętek; Wieslaw Bal; Kamycka A et al.
Source: Self-asserted source
Krzysztof Ostaszewski

Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?

Journal of Clinical Oncology
2022-06-01 | Journal article
DOI: 10.1200/jco.2022.40.16_suppl.e21544
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Krzysztof Ostaszewski

Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.

Journal of Clinical Oncology
2022-06-01 | Journal article
DOI: 10.1200/jco.2022.40.16_suppl.e21539
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Krzysztof Ostaszewski

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Cancers
2022-04-24 | Journal article
DOI: 10.3390/cancers14092123
PMID: 35565255
PMC: PMC9101360
Source: Self-asserted source
Krzysztof Ostaszewski

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence.

Journal of clinical medicine
2022-04-17 | Journal article
DOI: 10.3390/jcm11082239
PMID: 35456332
PMC: PMC9032972
Source: Self-asserted source
Krzysztof Ostaszewski

Efficacy of neoadjuvant therapy of stage IIIB-D or IV melanoma – real world evidence

European Journal of Surgical Oncology
2022-02 | Journal article
DOI: 10.1016/j.ejso.2021.12.291
Part of ISSN: 0748-7983
Source: Self-asserted source
Krzysztof Ostaszewski

Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma.

Cancers
2021-12-27 | Journal article
DOI: 10.3390/cancers14010110
PMID: 35008274
PMC: PMC8744603
Source: Self-asserted source
Krzysztof Ostaszewski

1087P The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma

Annals of Oncology
2021-09 | Journal article
DOI: 10.1016/j.annonc.2021.08.1472
Part of ISSN: 0923-7534
Source: Self-asserted source
Krzysztof Ostaszewski

1529P Treatment results in elderly patients (pts) diagnosed with locally advanced soft tissue sarcoma (STS)

Annals of Oncology
2021-09 | Journal article
DOI: 10.1016/j.annonc.2021.08.859
Part of ISSN: 0923-7534
Source: Self-asserted source
Krzysztof Ostaszewski

P-157 Mitomycin C, 5-Fluorouracyl and Doxorubicin combination as a second-line chemotherapy in unresectable and metastatic biliary tract carcinoma: results of the first stage

Annals of Oncology
2015-06 | Journal article
DOI: 10.1093/annonc/mdv233.157
Part of ISSN: 0923-7534
Source: Self-asserted source
Krzysztof Ostaszewski
How many people are using ORCID?